Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FOLR1 positive
i
Other names:
FOLR1, Folate Receptor Alpha, Ovarian Tumor-Associated Antigen MOv18, Adult Folate-Binding Protein, Folate Receptor 1 (Adult), Folate Receptor, Adult, Folate Receptor 1, KB Cells FBP, FR-Alpha, FOLR, FBP, Folate Binding Protein, FRalpha
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2348
Related biomarkers:
Expression
‹
›
Associations
(5)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)
Phase 2/3
Sutro Biopharma, Inc.
Sutro Biopharma, Inc.
Recruiting
Phase 2/3
Sutro Biopharma, Inc.
Recruiting
Last update posted :
04/19/2024
Initiation :
07/12/2023
Primary completion :
09/01/2025
Completion :
02/01/2026
FOLR1
|
FOLR1 expression • FOLR1 positive
|
gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer (NCT02317705)
Phase 2
On Target Laboratories, LLC
On Target Laboratories, LLC
Completed
Phase 2
On Target Laboratories, LLC
Completed
Last update posted :
06/21/2022
Initiation :
12/01/2014
Primary completion :
11/01/2015
Completion :
11/01/2015
FOLR1
|
FOLR1 positive
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I) (NCT02631876)
Phase 3
ImmunoGen, Inc.
ImmunoGen, Inc.
Completed
Phase 3
ImmunoGen, Inc.
Completed
Last update posted :
10/14/2020
Initiation :
03/02/2016
Primary completion :
01/01/2019
Completion :
01/01/2020
FOLR1
|
FOLR1 positive
|
paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal
Share
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.